| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -0.6 | -0.7 |
| EPS (diluted, $ a share) | $-0.17 | $-0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BBLG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bone Biologics Corp: key numbers
- Share price
- $0.2942Close, Nov 16
- Market cap
- $997K
- Shares outstanding
- 3.39MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bone Biologics Corp
All →Bone Biologics Shareholder Meeting
Bone Biologics Corp held its Annual Meeting of stockholders on September 28, 2026, where shareholders elected four directors and ratified Weinberg & Company, P.A. as the independent auditor. Stockholders also approved a potential reverse stock split at a ratio between 1-for-2 and 1-for-10 and authorized the potential issuance of shares underlying warrants in excess of 20% of outstanding stock to comply with Nasdaq rules.
Bone Biologics Nasdaq/NYSE Compliance Notice
Bone Biologics Corp received a deficiency notice from Nasdaq on September 10, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, until March 9, 2027, to regain compliance and intends to seek shareholder approval for a reverse stock split to address the deficiency.
- Counterparty
- Nasdaq
- Term
- 180 days